Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis

References

• Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35(3):283–289.
   PubMed Web of Science ®Google Scholar
• David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Adv Exp Med Biol. 2017;1027:21–37.
   PubMed Web of Science ®Google Scholar
• Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl. 1):S8–16.
   PubMed Web of Science ®Google Scholar
• Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315–1327.
   PubMed Web of Science ®Google Scholar
• Paternoster L, Standl M, Chen CM, et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet. 2011;44(2):187–192.
   PubMedGoogle Scholar
• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;21:4(1):1.
   Google Scholar
• Drucker AM, Wang AR, Li WQ, et al. The burden of atopic dermatitis: summary of a report for the national eczema association. J Invest Dermatol. 2017;137(1):26–30.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–S76.
   PubMed Web of Science ®Google Scholar
• Onoue A, Kabashima K, Kobayashi M, et al. Induction of eosinophil- and Th2-attracting epidermal chemokines and cutaneous late-phase reaction in tape-stripped skin. Exp Dermatol. 2009;18(12):1036–1043.
   PubMedGoogle Scholar
• Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002;3(7):673–680.
   PubMed Web of Science ®Google Scholar
• Ito T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med. 2005;202(9):1213–1223.
   PubMed Web of Science ®Google Scholar
• Salimi M, Barlow GL, Saunders SP, et al. A role for IL-25 and IL-33-driven type2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013;210(13):2939–2950.
   PubMed Web of Science ®Google Scholar
• Bautista DM, Wilson SR, Hoon MA. Why we scratch an itch: the molecules, cells and circuits of itch. Nature Neuroscience. 2014;17(2):175–182.
   PubMedGoogle Scholar
• Feld M, Garcia R, Buddenkotte J, et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500–508.
   PubMed Web of Science ®Google Scholar
• Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of T(H)2/ T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344–1354.
   PubMed Web of Science ®Google Scholar
• Noda S, Suárez-Fariñas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136(5):1254–1264.
   PubMed Web of Science ®Google Scholar
• Shreberk-Hassidim R, Ramot Y, Zlotogorski A. Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol. 2017;76(4):745–753.e19.
   PubMed Web of Science ®Google Scholar
• Szalus K, Trzeciak M, Nowicki RJ. JAK-STAT inhibitors in atopic dermatitis from pathogenesis to clinical trials results. Microorganisms. 2020;8(11):1743.
   PubMed Web of Science ®Google Scholar
• Nakashima C, Yanagihara S, Otsuka A. Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors. Allergol Int. 2022;71(1):40–46.
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36.
   PubMed Web of Science ®Google Scholar
• Ihle JN. The stat family in cytokine signaling. Curr Opin Cell Biol. 2001;13(2):211–217.
   PubMed Web of Science ®Google Scholar
• Chapman S, Kwa M, Gold LS, et al. JAK inhibitors in dermatology: a comprehensive review, part 1. J Am Acad Dermatol. 2021;86(2):406–413.
   PubMedGoogle Scholar
• Xin P, Xu X, Deng C, et al The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020;80:106210.
   PubMed Web of Science ®Google Scholar
• Montilla AM, Gómez-García F, Gómez-Arias PJ, et al. Scoping review on the use of drugs targeting JAK/STAT pathway in atopic dermatitis, vitiligo, and alopecia areata. Dermatol Ther (Heidelb). 2019;9(4):655–683.
   PubMed Web of Science ®Google Scholar
• Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol. 1999;17(1):701–738.
   PubMed Web of Science ®Google Scholar
• Junttila IS. Tuning the cytokine responses: an update on Interleukin (IL)-4 and IL-13 receptor complexes. Front Immunol. 2018;7;9:888.
   Google Scholar
• He H, Guttman-Yassky E. JAK Inhibitors for atopic dermatitis: an update. Am J Clin Dermatol. 2019;20(2):181–192.
   PubMed Web of Science ®Google Scholar
• Rochman Y, Kashyap M, Robinson GW, et al. Thymic stromal lymphopoietin-mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL-7-induced signaling. Proc Natl Acad Sci U S A. 2010;107(45):19455–19460.
   PubMed Web of Science ®Google Scholar
• Ferretti E, Corcione A, Pistoia V. The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment. J Leukoc Biol. 2017;102(3):711–717.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. OLUMIANT® (baricitinib). Highlights of Prescribing Information; May 2018 [cited 2022 Jan 26. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/207924s000lbl.pdf.
   Google Scholar
• European Medicines Agency. Baricitinib (Olumiant): summary of product characteristics. 2017 [cited 2022 Jan 27]. Available from: http://ec.europa.eu/health/documents/communityregister/2017/20170213136870/anx_136870_en.pdf.
   Google Scholar
• Calabrese L, Malvaso D, Chiricozzi A, et al. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis. Expert Opin Investig Drugs. 2020;29(10):1089–1098.
   PubMed Web of Science ®Google Scholar
• Markham A. Baricitinib: first global approval. Drugs. 2017 Apr;77(6):697–704.
   PubMed Web of Science ®Google Scholar
• Kubo S, Nakayamada S, Sakata K, et al Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system. Front Immunol. 2018;28;9:1510.
   Google Scholar
• Liu X, Michael S, Bharti K, et al. A biofabricated vascularized skin model of atopic dermatitis for preclinical studies. Biofabrication. 2020;9:12(3):035002.
   Google Scholar
• Australian Product Information OLUMIANT® (baricitinib). Highlights of prescribing information. Apr 2021 [cited Jan 27, 2022]. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01225-1&d=20220127172310101
   Google Scholar
• Shi JG, Chen X, Lee F, et al. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. J Clin Pharmacol. 2014;54(12):1354–1361.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Upadacitinib (Rinvoq): summary of product characteristics; 2021 [cited Jan 27, 2022] Available from: https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_it.pdf
   Google Scholar
• Duggan S, Keam SJ. Upadacitinib: first approval. Drugs. 2019;79(16):1819–1828.
   PubMed Web of Science ®Google Scholar
• Parmentier JM, Voss J, Graf C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2(1):23.
   PubMedGoogle Scholar
• US Food and Drug Administration. RINVOQ® (upadacitinib). Highlights of Prescribing Information; 2019 [cited Jan 27, 2022]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211675s000lbl.pdf
   Google Scholar
• Mohamed MF, Zeng J, Jiang P, et al. Use of early clinical trial data to support thorough QT study waiver for upadacitinib and utility of food effect to demonstrate ECG assay sensitivity. Clin Pharmacol Ther. 2018;103(5):836–842.
   PubMed Web of Science ®Google Scholar
• Song T, Pavel AB, Peng X, et al. Upadacitinib treatment of atopic dermatitis patients leads to reductions in epidermal hyperplasia and cellular infiltrates [abstract no. 1024]. J Investig Dermatol. 2019;5 Suppl.(5):S177.
   Google Scholar
• Beck LA, Silverberg JI, Grebe K, et al. Eosinophil count and serum immunoglobulin E levels in atopic dermatitis: analysis of upadacitinib phase 2 study findings [abstract no. 376]. J Allergy Clin Immunol. 2019;143(2):AB125.
   Google Scholar
• European Medicines Agency. Abrocitinib (Cibinqo): summary of product characteristics; 2021 [cited Jan 27, 2022]. Available from: https://www.ema.europa.eu/en/documents/overview/cibinqo-epar-medicine-overview_it.pdf
   Google Scholar
• European Medicines Agency. Abrocitinib (Cibinqo): product information; 2021 [cited 2022 Jan 27]. Available from: https://www.ema.europa.eu/en/documents/product-information/cibinqo-epar-product-information_en.pdf
   Google Scholar
• Peeva E, Hodge MR, Kieras E, et al. Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: a phase 1, randomized, placebo-controlled, dose-escalation study. Br J Clin Pharmacol. 2018;84(8):1776–1788.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Forman SB, Bissonnette R, et al. Efficacy and safety of oral janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–1379.
   PubMed Web of Science ®Google Scholar
• Soto E, Banfield C, Gupta P, et al. Kinetic-pharmacodynamic model of platelet time course in patients with moderate-to-severe atopic dermatitis treated with oral janus kinase 1 inhibitor abrocitinib. CPT Pharmacometrics Syst Pharmacol. 2020;9(10):553–560.
   PubMedGoogle Scholar
• US Food and Drug Administration. JAKAFI® (ruxolitinib). Highlights of Prescribing Information; May 2019 [cited Jan 26, 2022]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202192s017lbl.pdf
   Google Scholar
• US Food and Drug Administration. OPZELURA® (ruxolitinib). Highlights of prescribing information; Sep 2021 [cited 2022 Jan 26]. Available from: https://www.opzelura.com/prescribing-information.pdf
   Google Scholar
• Ruxolitinib cream investigator’s brochure. Wilmington DE: Incyte Corporation; [cited 2022 Jan 26]. Available from: https://www.opzelura.com/prescribing-information.pdf
   Google Scholar
• Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–3117.
   PubMed Web of Science ®Google Scholar
• Scuron MD, Fay BL, Connell AJ, et al. Ruxolitinib cream has dual efficacy on pruritus and inflammation in experimental dermatitis. Front Immunol. 2021;11:620098.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol. 2011;131(9):1838–1844.
   PubMed Web of Science ®Google Scholar
• Tobacco J. JT receives manufacturing and marketing approval of CORECTIM® ointment 0.5% for the treatment of atopic dermatitis in Japan; 2020 January 23 [cited 2022 Jan 26]. Available from: https://www.jt.com/media/news/2020/pdf/20200123_E01.pdf.
   Google Scholar
• Tobacco J. JT receives approvals of CORECTIM® ointment 0.25% and CORECTIM® ointment 0.5% for the treatment of pediatric atopic dermatitis in Japan; March 23, 2021 [cited 2022 Jan 26]. Available from: https://www.jt.com/media/news/2021/pdf/20210323_E1.pdf.
   Google Scholar
• Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Infamm Res. 2015; 64(1) 41–51.
   PubMed Web of Science ®Google Scholar
• Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents. Exp Dermatol. 2018;27(1):22–29.
   PubMed Web of Science ®Google Scholar
• Amano W, Nakajima S, Yamamoto Y, et al. JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation. J Dermatol Sci. 2016;84(3):258–265.
   PubMedGoogle Scholar
• Nakagawa H, Nemoto O, Yamada H, et al. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis. J Dermatol. 2018;45(6):701–709.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723–1736.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Faleri S, Saraceno R, et al. Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert Rev Clin Immunol. 2015;11(4):443–455.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. XELJANZ® (tofacitinib). Highlights of prescribing information; September 2020 [cited 2022 Jan 26]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203214s026lbl.pdf
   Google Scholar
• Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor,CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010;7(1):41.
   PubMedGoogle Scholar
• Fukuyama T, Ehling S, Cook E, et al. Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis. J Pharmacol Exp Ther. 2015;354(3):394–405.
   PubMed Web of Science ®Google Scholar
• Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572–582.
   PubMed Web of Science ®Google Scholar
• Kim BS, Sun K, Papp K, et al. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82(6):1305–1313.
   PubMed Web of Science ®Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863–872.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018;178(2):424–432.
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: a phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study. J Am Acad Dermatol. 2020;82(4):823–831.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016;175(5):902–911.
   PubMed Web of Science ®Google Scholar
• Nogueira M, Torres T. Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib. Dermatol Pract Concept. 2021;11(4):e2021145.
   PubMedGoogle Scholar
• Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927–940.
   PubMed Web of Science ®Google Scholar
• Caputo V, Strafella C, Cosio T, et al. Pharmacogenomics: an update on biologics and small-molecule drugs in the treatment of psoriasis. Genes (Basel). 2021;12(9):1398.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy. Expert Opin Drug Metab Toxicol. 2014;10(12):1703–1710.
   PubMed Web of Science ®Google Scholar
• Guis S, Balandraud N, Bouvenot J, et al. Influence of −308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid- arthritis. Arthritis Rheum. 2007;57(8):1426–1430.
   PubMed Web of Science ®Google Scholar
• Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet. 2008;17(22):3532–3538.
   PubMed Web of Science ®Google Scholar
• Costanzo A, Bianchi L, Flori ML, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018;179(5):1072–1080.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169(2):458–463.
   PubMed Web of Science ®Google Scholar
• Talamonti M, Galluzzo M, van den Reek JM, et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol. 2017;177(2):489–496.
   PubMed Web of Science ®Google Scholar
• Vasilopoulos Y, Sarri C, Zafiriou E, et al. A pharmacogenetic study of ABCB1 polymorphisms and cyclosporine treatment response in patients with psoriasis in the Greek population. Pharmacogenomics J. 2014;14(6):523–525.
   PubMedGoogle Scholar
• Grželj J, Mlinarič-Raščan I, Marko PB, et al Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis. Biomed Pharmacother. 2021;138:111456.
   PubMedGoogle Scholar
• Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519–531.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol. 2019;80(4):913–921.e9.
   PubMed Web of Science ®Google Scholar
• Kay J, Harigai M, Rancourt J, et al. Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD Open. 2020;6(3):e001370.
   PubMedGoogle Scholar
• Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–1276.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl 2):ii111–ii115.
   PubMed Web of Science ®Google Scholar
• Koride S, Nayak S, Banfield C, et al. Evaluating the role of Janus kinase pathways in platelet homeostasis using a systems modeling approach. CPT Pharmacometr Syst Pharmacol. 2019;8(7):478–488.
   PubMedGoogle Scholar
• Kaser A, Brandacher G, Steurer W, et al. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 2001;98(9):2720–2725.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884.
   PubMed Web of Science ®Google Scholar
• Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv musculoskelet Dis. 2020;12:1759720X20936059.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018;9:2061.
   PubMed Web of Science ®Google Scholar
• Waickman AT, Park JY, Park JH. The common gamma-chain cytokine receptor: tricks-and-treats for T cells. Cell Mol Life Sci. 2016;73(2):253–269.
   PubMed Web of Science ®Google Scholar
• Gadina M, Hilton D, Johnston JA, et al. Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol. 2001;13(3):363–373.
   PubMed Web of Science ®Google Scholar
• Boisson-Dupuis S. The monogenic basis of human tuberculosis. Hum Genet. 2020;139(6–7):1001–1009.
   PubMedGoogle Scholar
• Jindal AK, Suri D, Guleria S, et al. Recurrent salmonella typhi infection and autoimmunity in a young boy with complete IL-12 receptor β1 deficiency. J Clin Immunol. 2019;39(4):358–362.
   PubMedGoogle Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
   PubMed Web of Science ®Google Scholar
• Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatology. 2017;153(10):1036–1042.
   PubMed Web of Science ®Google Scholar